Scancell gains on Phase I/II melanoma data

Scancell Holdings plc (LSE:SCLP; Xetra:SCP) added L3 .75 (12%) to L34 in London on Tuesday after reporting data from an ongoing open-label Phase I/II trial of SCIB1 to treat stage III/IV metastatic melanoma.

Among the 16 SCIB1-treated patients with resected metastatic melanoma, none had died and four (25%) had progressed 20-39 months after starting the trial. Scancell said the data "compare favourably" to the results of a previous peptide vaccine trial in which 19% of stage III patients and 33% of stage IV patients had died within 24 months of starting treatment and 52% of stage III and 50% of stage IV patients had progressed. ...